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Regulatory T cells (Treg) induce robust neuroprotection in murine models of neuroAIDS, in part, through
eliciting anti-inﬂammatory responses for HIV-1-infected brain mononuclear phagocytes (MP; macroph-
age and microglia). Herein, using both murine and human primary cell cultures in proteomic and cell
biologic tests, we report that Treg promotes such neuroprotection by an even broader range of
mechanisms than previously seen including inhibition of virus release, killing infected MP, and inducing
phenotypic cell switches. Changes in individual Treg-induced macrophage proteins were quantiﬁed
by iTRAQ labeling followed by mass spectrometry identiﬁcations. Reduction in virus release paralleled
the upregulation of interferon-stimulated gene 15, an ubiquitin-like protein involved in interferon-
mediated antiviral immunity. Treg killed virus-infected macrophages through caspase-3 and granzyme
and perforin pathways. Independently, Treg transformed virus-infected macrophages from an M1 to
an M2 phenotype by down- and up- regulation of inducible nitric oxide synthase and arginase 1,
respectively. Taken together, Treg affects a range of virus-infected MP functions. The observations
made serve to challenge the dogma of solitary Treg immune suppressor functions and provides novel
insights into how Treg affects adaptive immunosurveillance for control of end organ diseases, notably
neurocognitive disorders associated with advanced viral infection.
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Introduction
HIV-1 associated neurocognitve disorders (HAND) commonly
follow progressive virus infection in the infected human host.
1
Clinical disease features range in severity from subtle deﬁcits to
incapacitating dementia and include asymptomatic neurocogni-
tive impairment, mild neurocognitive disorder, and HIV-associ-
ated dementia (HAD).
2 Severe dementia is now rare since the use
of antiretroviral therapy (ART).
3 Notably, cognitive impairment
is associated, in measure, with immune suppression and a vicious
cycle of viral replication, ingress of perivascular macrophages, and
neuroinﬂammation.
4 Substantive neuropathological ﬁndings, in
the era of ART, are diminished and described as neuronal
dysfunction without loss.
5 The control and diagnosis of HAND
remains poorly understood despite considerable research efforts.
6
Recent research demonstrated a role for adaptive immunity and
speciﬁcally CD4+T cells in neurodegenerative diseases.
7-11 Works
performed by others and in our laboratories, both in murine
models of HAND and Parkinson’s disease (PD), demonstrated that
CD4+CD25+ Treg serve to attenuate brain mononuclear phago-
cyte (MP; macrophage and microglia) inﬂammation and sustain
neuroprotection.
7,9 Nonetheless, the mechanism underlying such
Treg-associated neuroprotective functions remains incompletely
understood.
12 Primary roles for Treg rests in the cells abilities to
provide self-tolerance.
13 Acting as a suppressor, its role in HIV
disease remains highly controversial.
14-17 Indeed, it has been
suggested that Treg play detrimental roles since they suppress the
HIV-speciﬁc immune response and inhibit virus clearance.
18,19
In contrast, others posit a beneﬁcial role for Treg through
suppression of immune hyperactivation and control of viral
load.
20-23 In support of the latter is Treg’s known role in simian
immunodeﬁciency virus (SIV) infection in sooty mangabeys and
its function as an elite suppressor to human immunodeﬁciency
virus (HIV) infection.
24,25 The similarity shared in these reports
rests in maintenance of Treg frequency and function to limit
generalized immune activation commonly seen during advanced
HIV disease.
26
We now demonstrate a multifaceted role for Treg for HIV-
1-infected MP. Such a role serves a range of regulatory
* To whom correspondence should be addressed. Howard E. Gendelman
Department of Pharmacology and Experimental Neuroscience University of
Nebraska Medical Center 985800 Nebraska Medical Center Omaha, NE
68198-5880.Phone:4025598920.Fax:4025593744.E-mail:hegendel@unmc.edu.
Yaoying Zeng The Institute for Tissue Transplantation and Immunology Jinan
University Guangzhou, Guangdong 510632, China. Phone: 8620-85226219.
E-mail: zengyaoying@gmail.com.
† These authors contributed equally to this manuscript.
‡ Department of Pharmacology and Experimental Neuroscience, Univer-
sity of Nebraska Medical Center.
§ Jinan University.
| Department of Biostatistics, University of Nebraska Medical Center.
10.1021/pr1009178  2010 American Chemical Society Journal of Proteome Research 2010, 9, 6759–6773 6759
Published on Web 10/18/2010functions acting to control disease such as suppression of
viremia and modulation of HIV-1-infected macrophage neu-
rotoxic activities. In support of such claims, we used isobaric
tag for relative and absolute quantitation (iTRAQ) of proteins
to identify differential protein expression between HIV-1-
infected bone marrow-derived macrophages (BMM) with and
without Treg. We found changes consistent with enhanced
antiretroviral immunity through Treg-induced upregulation of
interferon (IFN)-induced gene products. This was seen among
a broad range of related protein expression changes linked to
antiviral responses. Second, we showed that Treg utilizes
caspase-3 and granzyme/perforin pathways to kill virus-
infected cells. Third, Treg reduced neurotoxic secretions in vitro
through its abilities to transform HIV-1-infected macrophages
from an M1 to an M2 phenotype. These observations made in
murine Treg-BMM cocultures were replicated separately in
human Treg-monocyte-derived macrophages (MDM) cocul-
tures. Taken together, these data demonstrate that Treg serve
as effectors for virus-infected macrophages and suppressors
for inﬂammation and as such, exert immune surveillance
functions relevant to ongoing HIV infection and neuroAIDS.
Materials and Methods
Animals. C57BL/6J male mice (8-10 wk old) were purchased
from The Jackson Laboratory and used for BMM and T cell
isolations. All animal procedures were in accordance with the
National Institutes of Health guidelines and were approved by
the Institutional Animal Care and Use Committee of the
University of Nebraska Medical Center.
Isolation and Cultivation of BMM. Femurs of the mice were
excised and ﬂushed with Dulbecco’s phosphate buffered saline
(DPBS) to obtain bone marrow-derived mononuclear cells.
Cells were passed through a 40 µm cell strainer to remove the
clumps and then centrifuged. Erythrocytes were removed using
ACK lysis buffer (Gibco, Grand Island, NY). After washing twice
with DBPS, cells were resuspended and plated in 6-well plates
at 1 × 106 cells/mL in 3 mL complete medium [RPMI 1640
supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 10 mM HEPES, 1× nonessential amino acids, 50
µM 2-mercaptoethanol, 100 U/mL penicillin, 100 µg/mL strep-
tomycin, and 2 µg/mL macrophage colony stimulating factor,
MCSF (Pﬁzer, Cambridge, MA)]. After 7 days differentiation,
cells were >98% CD11b+ as determined by ﬂow cytometry
(Supplemental Figure 1A).
Generation of HIV-1/VSV Pseudotype Virus and Assay of
Viral Infectivity. VSV pseudotyped HIV-1, YU2 (HIV-1/VSV) was
used to circumvent the required cellular receptors necessary
for HIV-1 to infect mouse cells. The HIV-1YU2/VSV pseudotypes
were generated by cotransfection of 3 µg of pYU2 and 1 µgo f
pHIT/G into 293T cells (per 1 × 106 cells) using the FuGENE 6
transfection reagent (Roche Diagnostics, Indianapolis, IN).
Pseudotyped virus stock was collected after 72 h post-trans-
fection. Because the pseudotyped virus only contains HIV-1YU2
genes, but not the glycoprotein gene of VSV, they could only
enter the mouse BMM once. The concentration of the virus
stock was determined by HIV-1p24 ELISA kit (PerkinElmer,
Boston, MA). We used a range of infective viral doses including
1, 2, and 3 pg of HIV-1p24/cell to infect BMM. This was done
to ensure a data set independent of multiplicity of infection
(MOI). After 24 h, the percentage of p24 positive cells was
determined by immunohistochemistry. As shown in Supple-
mental Figures 1B and 1C at 1 pg of HIV-1p24/cell >95% HIV-
1p24 immunoreactivity was observed. Further, the level of HIV-
1p24 staining increased in parallel to the infective dose. In
subsequent experiments, 1 pg of HIV-1p24/cell was used to
infect BMM. Virus was placed into the media for 24 h then
removed by vigorous washings with phosphate buffered saline
(PBS).
27
Isolation and Expansion of Mouse Tcon and Treg. CD4+ T
cell subsets were isolated using previously described techni-
ques.
28,29 Brieﬂy, immune cells were isolated from the spleens
and lymph nodes (inguinal, brachial, axillary, cervical and me-
senteric) by dissection, followed by mechanical dissociation by
pushing the organs through a 70 µm mesh ﬁlter. Cells were
washed with DPBS, erythrocytes were removed by the ACK lysis
buffer (Gibco) and cells washed twice more with PBS. The
processed cells were then passed through a mouse T cell enrich-
ment column (R&D Systems, Minneapolis, MN) for T cell negative
selection, followed by passage of the puriﬁed T cells through a
mouse T cell CD4 subset column (R&D Systems) for negative
selection of CD4+ T cells. CD4+ T cells were then labeled with
monoclonal antimouse CD25-PE antibody, then reacted with anti-
PE MicroBeads (Miltenyi Biotec, Auburn, CA) and passed through
the MACS column in a magnetic ﬁeld for positive selection of
CD25+ cells. The ﬂow through containing CD4+CD25- T cells
was used in these experiments and propagated as CD3/CD28-
activated conventional T cells (Tcon) (see below). The isolated
CD4+CD25+ cells retained on the column and then eluted were
used as Treg (Supplemental Figure 2A, Supporting Information).
T cell isolates were >91% (CD4+CD25+FoxP3+) and >96%
(CD4+CD25+) pure (Supplemental Figure 2B-D, Supporting
Information), respectively. Treg and Tcon were expanded ex vivo
using CD3/CD28 T cell expander Dynabeads (Invitrogen Dynal,
Oslo, Norway). The Dynabeads were added to cells plated in 24
well plates at 1 × 106 cells/mL in complete RPMI along with 1000
U/mL mouse rIL-2 (R&D Systems) for Treg cultures; whereas, 100
U/mL mouse rIL-2 was used for Tcon cell cultures. Cells were
expanded in culture for 10 days with half-media changes every
2-3 days. Treg remained >83% pure after expansion as deter-
mined by CD4+FoxP3+ staining (Supplemental Figure 2C, D,
Supporting Information). The function of Treg was evaluated by
lymphocyte proliferation suppression assay as described below
(Supplemental Figure 2E, F, Supporting Information). Mouse and
human T cells were cocultured only with same species mouse
and human macrophages.
Isolation and Culture of Human MDM. Peripheral blood
mononuclear cells (PBMC) from HIV-1, HIV-2, and hepatitis
seronegative human donors were obtained by leukophoresis
in full compliance and approval of the University of Nebraska
Medical Center Institution Review Board. Monocytes were
puriﬁed by countercurrent centrifugal elutriation.
30 Cells were
cultured in complete RPMI medium and maintained in a 37
°C and 5% CO2 atmosphere. On days 2 and 5, half of the
medium was exchanged. After seven days in culture, MDM
were infected with HIV-1ADA (a macrophage tropic viral strain)
at a MOI of 1 or left untreated (controls) in media devoid of
MCSF. On day 1 after infection, a full medium exchange was
performed followed by a half medium exchange every 2-3 days
thereafter in medium devoid of MCSF. On day 7 after infection,
cells were cocultured with activated Tcon or Treg (1:1) for an
additional 24 h. The 1:1 ratio of T cells to macrophages was
usedbaseduponourpriordatafromeffectorcelloptimization.
7-9
Moreover, further additions of Tregs in virus-infected mac-
rophage cocultures would eliminate all virus-infected cells and
preclude any subsequent proteomic testing (data not shown).
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CD8 T cell ratios from donor blood were determined prior to
starting all experiments with human cells. Tcon and Treg were
isolated from the same donor as cultured MDM. Human Tregs
were isolated from PBMC using the CD4+CD25+ Regulatory
T Cell Isolation Kit (Miltenyi Biotec). Brieﬂy, human Tregs were
isolated by ﬁrst depleting all non-CD4+ cells by indirect
magnetic labeling of cells with a cocktail of biotin-conjugated
monoclonal antihuman antibodies against CD8, CD14, CD16,
CD19, CD36, CD56, CD123, TCRγ/δ and CD235a; adding
antibiotin magnetic MicroBeads; and then passing cells through
a magnetic column and collecting the CD4+ enriched fraction.
Then CD4+CD25+ T cells were isolated by positive selection
using magnetic MicroBeads conjugated to monoclonal anti-
CD25 antibody and passing the cells over the magnetic column.
The eluted CD4+CD25- cells were used as Tcon, and the
retained CD4+CD25+ cells were used as Treg in these experi-
ments. Purity was determined by CD25-PE staining and detec-
tion by ﬂow cytometry (Supplemental Figure 3A, Supporting
Information). Treg and Tcon cells were expanded and activated
ex vivo using human Treg Expander Dynabeads (Invitrogen,
Carlsbad, CA). The function of expanded Treg was evaluated
by lymphocyte proliferation suppression assay (Supplemental
Figure 3B, Supporting Information). Human T cells were only
cocultured with human monocytes from the identical donors.
Flow Cytometry. Cells (1 × 106) were labeled with ﬂuores-
cently labeled antibodies to CD3, CD4, CD8, CD11b (eBio-
science, San Diego, CA), CD25 (BD Pharmingen, San Diego,
CA), and CD39 (R&D Systems). For CD39 staining, Alexa Fluor
488 donkey antisheep secondary antibody (Invitrogen) was
used. For intracellular staining, cells were ﬁxed, permeabilized
(FoxP3 staining kit, eBioscience, San Diego, CA) and stained
for HIV-1p24 (Beckman Coulter, Brea, CA), mouse FoxP3
(eBioscience), granzyme A (Santa Cruz Biotechnology, Santa
Cruz, CA), granzyme B (eBioscience) and perforin (eBioscience).
All the data were acquired on FACSCalibur ﬂow cytometer and
analyzed with CellQuest Software (Becton Dickinson, Franklin
Lakes, NJ). For lymphocyte proliferation suppression assay
(Supplemental Figures 2E, F, and 3B, Supporting Information),
Tcon were incubated with 1 µM carboxyﬂuorescein diacetate,
succinimidyl ester (CFSE) per 10 × 106 cells for 15 min and
washed twice with RPMI 1640 culture medium. Excluding the
control group, Tcon were cultured alone or with Treg at 2-fold
escalating ratios in ﬂat-bottom 96-well plates with addition of
Dynabeads Mouse T-Activator CD3/CD28. After 72 h, cells were
collected, Dynabeads were removed by DynaMag-15 magnet
(Invitrogen), and CFSE was measured by ﬂow cytometry.
Culture Fluids and Cell Lysates. After 7 days differentiation,
BMM were replated at 2 × 106 cells per well in 6-well plates.
HIV-1-infected BMM were cocultured with Dynabead-activated
Tcon or Treg at a ratio of 1:1. Twenty-four hours later, culture
supernatants were collected as conditioned medium 1 (CM1),
which contained soluble molecules from macrophages and/
or T cells. T cells were removed by PBS washing and 2 mL fresh
medium were added to each well. After another 24 h, culture
supernatants were collected as conditioned medium 2 (CM2),
which contained soluble molecules from macrophages only.
The cytokines and virions in conditioned medium were de-
tected by Cytometric Bead Array Mouse Inﬂammation kit (BD
Biosciences, San Jose, CA) and Alliance HIV-1p24 ELISA kit
(PerkinElmer, Boston, MA), respectively, according to manu-
factures’ protocols. For the cell lysates, macrophages were
washed using PBS and then air-dried in a laminar ﬂow hood.
For each plate, cells were lysed by 500 µL ice-cold lysis buffer
containing 0.05% sodium dodecyl sulfate (SDS, Bio-Rad, Her-
cules, CA) and 0.5 M triethylammonium bicarbonate (TEAB,
Sigma-Aldrich, St. Louis, MO). Lysates were clariﬁed by cen-
trifugation at 14 000× g at 4 °C for 45 min.
Confocal Microscopy and Immunocytochemical Assays. For
HIV-1p24 immunochemistry staining, mouse BMM or human
MDM were ﬁxed and permeabilized with acetone: methanol
(1:1, precooled to -20 °C) for 15 min at room temperature (RT).
Cells were washed 3 times with DPBS for 5 min each, then
blocked (10% normal goat serum in DPBS) for 30 min at RT.
Cells were incubated with mouse anti-HIV-1 p24 antibody (1:
20, Dako, Carpinteria, CA) in blocking buffer at 4 °C overnight.
Cells were washed with DPBS and incubated with secondary
antibody according to EnVision Kits (Dako). Brieﬂy, samples
were incubated with horse radish peroxidase (HRP) conjugated
polymer for 30 min at RT. After washing with DPBS, samples
were incubated with HRP substrate 3,3′-diaminobenzidine
(DAB) substrate-chromogen for 5-10 min at RT, which resulted
in brown-colored precipitate in HIV-1/VSV infected groups.
Pictures were taken with a light microscope (Nikon Eclipse
TS100). For detection of intracellular proteins after treatment,
BMM were ﬁxed by 4% paraformaldehyde (PFA) at 37 °C for
15 min and permeabilized by 0.2% Triton X-100 in DPBS at 4
°C for 30 min. Nonspeciﬁc activity was blocked by incubation
in 5% bovine serum albumin (BSA) in DPBS at room temper-
ature for 1 h. Cells were incubated with ﬂuorescence labeled
antibodies (granzyme B and perforin) and unlabeled primary
antibodies (tubulin and granzyme A) at RT for 3 h followed by
staining with Alexa Fluor 488 goat antimouse IgG or Alexa Fluor
546 goat antimouse IgG (Invitrogen), respectively, at RT for 2 h.
As for actin staining, we used Alexa Fluor 546 phalloidin. After
washing, cells were mounted with ProLong Gold antifade
reagent (Invitrogen) with DAPI and analyzed by Zeiss 510 Meta
Confocal Laser Scanning Microscope. Images were acquired
using the same parameters within groups stained with the same
protein. Human MDM detection of Apo2.7 was also stained
similarly using a phycoerythrin (PE) conjugated primary anti-
body (1:10, Beckman Coulter, Brea, CA). For T cell intracellular
staining of granzyme A, B and perforin, 2 × 105 cells were
sedimented on Shandon microscope slides (Thermo Fisher,
Waltham, MA) by centrifugation at 1200 rpm for 5 min then
covered with ProLong Gold antifade mounting solution (Invit-
rogen). For the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay, TUNEL and FLICA caspase
assays, cells were replated at 2 × 105 cells/well in 8-well
polystyrene culture slides for 24 h. Cells were infected with HIV-
1/VSV for 24 h, then cells were washed and cocultured with T
cells for 24 h before adding probes. The cytotoxic effects of
Tcon versus Treg secreted factors on HIV-1/VSV infected BMM
after 24, 48, and 72 h in transwell cocultures were determined
by MTT (Sigma) assay.
10 Mitochondrial membrane integrity
was assessed by JC-1 (Calbiochem, San Diego, CA) cell stainings
following the manufacturer’s suggested protocol. Caspase 1 and
caspase 3/7 activities were measured using the carboxyﬂuo-
roescein FLICA assay (Immunochemistry Technologies, Bloom-
ington, MN) according to the manufacturer’s protocol. TUNEL
was performed using the in situ cell death detection kit, AP
(Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s protocol. Brieﬂy, BMM were washed by DPBS,
ﬁxed by 4% PFA and permeabilized by 0.1% Triton X-100 in
0.1% sodium citrate. Subsequently, cells were incubated with
TUNEL working solution, which contains Terminal Deoxy-
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for 1 h. Apoptotic cells were identiﬁed as green ﬂuorescent
TUNEL positive cells by ﬂuorescence microscopy and were
normalized to total number of cells as determined by bright
ﬁeld images. In addition, the cell death was measured by trypan
blue staining.
iTRAQ Labeling. Protein concentrations of the cell lysates
were quantiﬁed with 2-D Quant Kit (GE Healthcare, Piscataway,
MA). Eighty micrograms of total protein was used from each
group. All samples were diluted to the same volume for
consistency. Proteins were further reduced, alkylated, digested
and iTRAQ labeled using iTRAQ Reagents Multiplex Kit (Applied
Biosystems, Carlsbad, CA) according to the manufacturer’s
protocol. Brieﬂy, proteins were reduced with 5 mM tris-(2-
carboxyethyl)phosphine (TCEP) at 60 °C for 1 h and blocked
with 10 mM methyl methanethiosulfonate (MMTS) at RT for
10 min. Then, the proteins were digested by 10 µg trypsin at
37 °C for 16-18 h. Peptides were then labeled with iTRAQ
reagent (114 for control, 115 for HIV-1/VSV, 116 for HIV-1/VSV
cocultured with Tcon, 117 for HIV-1/VSV cocultured with Treg)
at RT for 1 h, followed by adding 100 µL Milli-Q water to each
group to stop labeling reaction. The labeled peptides from the
four groups were combined and dried in a Speed Vac (Thermo,
Waltham, MA) to obtain a brown pellet, indicating efﬁcient
labeling.
OFFGEL Fractionation and Peptide Cleanup. For isoelectric
point (pI)-based peptide separation, we used the 3100 OFFGEL
Fractionator (Agilent Technologies, Santa Clara, CA, USA) with
a 12-well setup. Prior to electrofocusing, pooled peptides were
desalted using a mixed mode cation exchange cartridge (Wa-
ters, Milford, MA). Peptides were resuspended in a ﬁnal volume
of 1.8 mL 1× OFFGEL sample solution. The IPG gel strip
(Agilent Technologies, Santa Clara, CA) with a 3-10 linear pH
range was rehydrated with rehydration solution for 15 min
according to the protocol of manufacturer. Then, 150 µLo f
prepared sample was loaded in each well. Electrofocusing of
the peptides was performed using program 12-PE00. After
fractionation, samples were cleaned up using C-18 Spin
Column (Pierce, Rockford, IL). Finally, samples were dried in
a Speed Vac and stored at -80 °C until ready for analysis by
matrix-assisted laser desorption/ionization tandem mass spec-
troscopy (MALDI-MS/MS).
Matrix-Assisted Laser Desorption/Ionization (MALDI-MS/
MS). Peptide samples were spotted using the off-line Tempo C
MALDI Spotting System (Applied Biosystems, Carlsbad, CA).
Then, MS and MS/MS were performed using the 4800 MALDI-
TOF/TOF (Time Of Flight) mass spectrometer (Applied Bio-
systems). Mass spectrometry data were analyzed using Pro-
teinPilot 2.0 software (Applied Biosystems). The Tempo
LC-MALDI robotic spotting system equipped with a C18
reversed phase capillary column (AB Sciex, Foster City, CA) was
used to further fractionate peptides from OFFGEL fractions,
followed by data acquisition using 4800 MALDI TOF/TOF (AB
Sciex, Foster City, CA) as previously published.
31 Brieﬂy, after
using an in-house packed C18 column to separate fractions
by HPLC gradient based on hydrophobicity, LC fractions were
spotted onto MALDI 1232-spot format plates, with a spotting
interval of 24 s and applying 2.8 kV plate voltage. Data was
acquired from LC-MALDI spot fractions using 4800 MALDI
TOF/TOF equipped with a 200 Hz repetition rate Nd:YAG laser.
Spectrum from a total of 800 laser shots was accumulated for
each TOF MS spectrum between 800-4000 m/z. Data depend-
ent MS/MS mode was operated using CID gas and 2 kV
collision energy; programmed laser stop conditions were
employed for the accumulation of MS/MS spectra from
800-4000 laser shots.
Primary Mouse Neuronal Cytotoxicity Assays. Eighteen-
day-old embryonic fetuses were obtained from terminally
anesthetized pregnant C57BL/6J mice.
9 Cerebral cortices were
dissociated and digested into a single-cell suspension, which
was then cultured at a density of 2.0 × 105 cells/well in poly-
D-lysine-coated 24-well plates with complete neurobasal me-
dium supplemented with 2% B27, 1% penicillin/streptomycin,
and 0.5 mM L-glutamine (Invitrogen, Carlsbad, CA). After 8-12
days, neuron-enriched cultures showed typical branching
dendrites. Mature neurons were treated with 10% CM1 and
CM2, respectively. Twenty-four hours later, neurons were ﬁxed/
permeabilized and then stained for tubulin. Dendrite morphol-
ogy was observed by ﬂuorescent microscopy (Zeiss, Thorn-
wood, NY).
Western Blot Analyses. For Western blots, 10 µg of protein
from each total cell lysate was electrophoretically separated on
NuPAGENovex 4-12% Bis-Tris Gels (Invitrogen) and elec-
trotransfered to polyvinylidene membranes (Bio-Rad, Hercules,
CA). Membranes were incubated with respective primary
antibodies at 4 °C overnight and HRP-conjugated secondary
antibodies (1:2000, Santa Cruz Biotechnology, Santa Cruz, CA)
at RT for 1 h. HRP activity was visualized by using a SuperSignal
West Pico Chemiluminescent substrate (Pierce, Rockford, IL).
Band intensity was measured using ImageJ and normalized to
 -actin (1:1000, Santa Cruz Biotechnology). Antibodies used for
Western blot assays included murine anti-iNOS (1:500) and
Arg-1 (1:1000, BD Transduction Laboratories, Franklin Lakes,
NJ), Caspase-1 (1:500, Santa Cruz Biotechnology), Caspase-3
(1:1000, Cell Signaling, Danvers, MA), NDUFS3 (1:1000, Invit-
rogen, Carlsbad, CA, USA), Phospho-p38 (1:500, Santa Cruz
Biotechnology), perforin (1:500, eBioscience, San Diego, CA,
USA), STAT1 (1:2000, Santa Cruz Biotechnology), ISG15 (1:1000,
Cell Signaling, Danvers, MA, USA), and HIV-1p24 (1:500, Dako,
Carpinteria, CA).
Assays for HIV-1 p24, cAMP and NO Detection. Detection
of HIV-1p24 by ELISA from culture supernatants was used to
assay viral particle release according to the manufacturer’s
protocol (PerkinElmer, Boston, MA). Intra- and extracellular
cAMP was quantiﬁed using the Direct Cyclic AMP Enzyme
Immunoassay (Assay Designs, Plymouth Meeting, PA). NO was
measured in culture supernatants using the Griess reagent
system (Promega, Madison, WI).
Statistical Analyses. Data presented are representative of
three or more individual experiments. Statistical analyses were
performed by one-way ANOVA with Bonferroni posttest and
Student’s t test by using GraphPad Prism version 4.0c for
Macintosh (GraphPad Software, San Diego, CA). Strict ﬁltering
of iTRAQ raw data was accomplished by log-transforming the
raw data from 3 independent experiments then normalizing
using a two-stage linear model macros written by Mayo
Clinic.
32 Protein/peptide records were excluded from further
analysis if the corresponding conﬁdence values were less than
50, or less than 10 copies of peptide records across all three
experiments per corresponding proteins were available. These
ﬁltering procedures resulted in a subset of 1394 proteins for
later analysis. A one-way ANOVA with unequal variances was
ﬁtted to the corresponding normalized data for each protein.
The associated p-values from ratios of labeled samples (from
t test) were adjusted controlling for False Discovery Rate (FDR)
via a method proposed by Benjamini and Hochberg
33 and those
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(strictly ﬁltered data).
Results
Treg Enhance Interferon Related Protein Expression and
Proteins Involved in Apoptosis. Treg subverts brain MP
functions and elicits neuroprotective activities in a HIV-1/VSV
murine model of HIV encephalitis (HIVE) and in the 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s.
8,9 To
determine the protein composition up- or down-regulated in
infected BMM cocultivated with Treg we used iTRAQ assays
followed by OFFGel fractionation and MALDI TOF/TOF mass
spectrometry. HIV-1/VSV infected BMM in solitary culture and
with Tcon were also used for comparisons (Supplemental Table
2, Supporting Information). Analyses of proteomic changes in
cocultures were done using comparisons to HIV-infected BMM
alone in order to distinguish changes in the proteome that
occur in the setting of HIV due to T cell interactions/responses
from those that occur solely because of HIV infection. A
combination treatment with Treg and Tcon was not used as
this would represent total CD4+ T cell populations and
preclude analyses of CD4+ T cell subsets. A total of 3553 unique
proteins were identiﬁed from the three separate experiments
performed. After strict data ﬁltering (described in Materials and
Methods) we identiﬁed 293 proteins changed upon HIV-1/VSV
infection compared to uninfected BMM, 21 proteins changed
in Treg cocultures compared to HIV-1/VSV infection alone, and
20 proteins were differentially regulated in Tcon cocultures
compared to HIV-1/VSV infection alone. Proteome alterations
due to Treg treatment were strongly associated with antiviral
immune responses and apoptosis. In addition, proteins in-
volved in cell shape/motility and metabolism were also un-
covered (Table 1 and Supplementary Table 2). These changes
pointed to an underappreciated role for Treg as effector cells
and as such led us to explore aspects of antiviral immunity and
induced apoptosis for the infected BMM as the proteome
changes suggested.
Treg Suppression of Virus Release is Linked to the
Upregulation of Interferon Stimulated Gene 15 (ISG15). To
elucidate the mechanisms by which Treg could alter functional
outcomes for HIV-1-infected macrophages, we ﬁrst focused on
validating the enhanced antiviral immune response supported
by protein changes observed after strict ﬁltering of the iTRAQ
data. Treg coculture resulted in upregulation of BMM expres-
sion of signal transducer and activator of transcription 1
(STAT1) and ISG15 (Figure 1A, B) found in type I IFN antiviral
signaling.
34 Since ISG15 was reported to inhibit release of HIV-1
virions, we assayed whether the increased ISG15 expression
observed resulted in reduced virion release.
34 HIV-1p24 levels
in BMM cell lysates and culture supernatants were measured
by Western blotting and ELISA. No changes in HIV-1p24 were
observed between HIV-1/VSV infected BMMs and HIV-1/VSV
infected BMMs cocultured with CD3/CD28-activated Treg or
Tcon in cell lysates (Figure 1C). This reﬂected that the pseudot-
yped virus is not capable of spreading viral infection, so the
level of HIV-1p24 is dependent only on the initial infective dose
(Supplemental Figures 1B, C, Supporting Information). How-
ever, ELISA tests of culture supernatant ﬂuids showed both
Table 1. Treg-Induced HIV-1/VSV BMM Proteins Identiﬁed After Strict Filtering of iTRAQ Data
a
name of protein
NCBI accession
number M.W. [kDa] 117/115
b P-value
c function
Granzyme A 6754102 28.6 2.1574 0.0040 Induces apoptosis of pathogen infected cells
Granzyme B 7305123 27.5 4.0877 0.0000 Induces apoptosis of pathogen infected cells
Granzyme D 3334466 27.6 3.9000 0.0000 Induces apoptosis of pathogen infected cells
ISG15 ubiquitin-like modiﬁer 80476034 17.9 1.6406 0.0024 Ubiquitin-like protein that is conjugated to intracellular
target proteins after IFN-alpha or IFN-beta stimulation.
May also be involved in autocrine, paracrine and
endocrine mechanisms, as in cell-to-cell signaling,
possibly partly by inducing IFN-gamma secretion by
monocytes and macrophages. Seems to display antiviral
activity during viral infections
Interferon-induced
guanylate-binding protein 2
37999845 66.7 2.6956 0.0000 IFN immune response. Binds GTP, GDP and GMP.
Guanylate-binding protein 5 37999681 66.9 2.2865 0.0039 IFN immune response
Interferon-inducible GTPase 1 88909159 47.6 1.9876 0.0139 May play a role in resistance to intracellular pathogens.
Has low GTPase activity. Has higher afﬁnity for GDP
than for GTP.
Immune-responsive gene
1 protein
119364598 53.8 1.9306 0.0262 Immune response - IFN-inducible gene
Tryptophanyl-tRNA synthetase,
cytoplasmic
51704226 54.4 1.1543 0.0117 IFN-gamma induced protein. Protein synthesis
Prolow-density lipoprotein
receptor-related protein 1
81867523 504.7 0.7061 0.0077 Endocytic receptor involved in endocytosis and in
phagocytosis of apoptotic cells. Involved in cellular lipid
homeostasis.
Twinﬁlin-1 92090648 40.1 0.9064 0.0040 Actin-binding protein involved in motile and
morphological processes
Sialic acid binding Ig-like
lectin 1, sialoadhesin
187954777 183.1 0.8250 0.0186 Macrophage-restricted adhesion molecule that mediates
sialic-acid dependent binding to lymphocytes.
Pyruvate dehydrogenase
(lipoamide) beta
63101525 38.9 0.8850 0.0276 Metabolism
a Protein quantitation was made using iTRAQ as performed on cell lysates of BMM from three separate experiments.
b These experiments compared
HIV-1/VSV infected murine BMM that were cocultured with murine Treg (117 label) to HIV-1/VSV infected murine BMM cultured alone (115 label).
c P-value after Benjamini and Hochberg FDR adjustment.
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blotting showed increased STAT1 phosphorylation in HIV-1/VSV infected BMM cocultured with Treg group. Data shown are
representative of three independent experiments. (B) Western blotting showed dramatically increased free ISG15 and ISGylated
proteins in HIV-1/VSV infected BMM cocultured with Treg group. Data shown are representative of three independent experiments.
(C) Western blotting showed no change of HIV-1 p24 expression between HIV-1/VSV infected BMM group, HIV-1/VSV infected
BMM group cocultured with Tcon group and HIV-1/VSV infected BMM group cocultured with Treg group. In this study the
pseudotyped virus we used could enter the mouse BMM once, so the level of p24 staining is dependent only on the infective
dose. Data shown are representative of three independent experiments. (D) Both Tcon and Treg could inhibit HIV-1 release
determined by HIV-1 p24 ELISA. Data shown are representative of three independent experiments. ***p < 0.001. (E) Proposed
pathways involved in initiating antiviral immune response in HIV-1-infected macrophages, which was enhanced by Treg and
Tcon. In macrophages, engagement of TLR3 by HIV derived dsRNA in endosomes mediates IFN-R/ /λ production. TLR3 induces
a Trif-dependent pathway, which recruits kinases (TBK1, IKK  and IKKR γ) that mediate activation of the transcription factors
IRF3 and NF-κB. Together with IRF7, IRF3 and NF-κB translocate into the nucleus and bind to positive regulatory domains on the
Ifn genes promoter, leading to Ifn transcription. Secreted IFNs signal through binding to their cognate receptors (IFNAR1 and
IFNAR2) and then recruit kinases (TYK2 and JAK1) leading to translocation of phosphorylated transcription factors (STAT1 and
STAT2) and IRF9 to the nucleus where binding to the enhancer region of the ifn promoter and isg promoter occurs, which leads
to the activation and nuclear transport of ISGF3 and induction of ISRE to produce IFNs and ISGs. Both IFNs and ISGs could inhibit
ubiquitination of HIV Gag and Tsg101, which results in less virus release. With unknown mechanisms, Treg exhibit much greater
capacity to enhance the antiviral immune response than Tcon.
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1p24 concentrations (Figure 1D). Moreover, Treg more than
Tcon (the inhibition rate is 79 versus 45%, respectively)
inhibited HIV-1p24 release in culture ﬂuids. We posit that such
ﬁndings could result from stimulation of autocrine/paracrine
pathways linked to innate IFN antiviral immunity regulated by
Treg (Figure 1E).
Treg Kills Infected BMM. In the past decade following Treg
discovery, substantive research has focused on the mechanisms
for immune tolerance by Treg through its inhibitory molecule
expression and secretion, such as CTLA-4, GITR, IL-10 and
TGF-  (reviewed by Zhu and Paul
35). However, Tregs also
exhibit perforin-dependent cytotoxicity against autologous
target cells
36 indicating that Treg can act as natural cytotoxic
cells, like natural killer cells and cytotoxic T lymphocytes. Based
on such prior ﬁndings and our observations of granzymes in
the infected BMM lysates treated with Treg by mass spectrom-
etry, we hypothesized that Treg may induce HIV-1-infected
macrophage death to deplete the cell source of neurotoxic
factors. To test this hypothesis, we used terminal deoxynucle-
otidyl transferase dUTP nick end labeling (TUNEL) assay to
assess the cytotoxicity of Treg against HIV-1/VSV infected
BMM. Greater than 50% of BMMs were TUNEL positive in Treg
treated cocultures (Figure 2A, B). The ﬁndings mirrored trypan
blue exclusion tests (Figure 2A, B). Cytotoxicity of Treg was
<10% in uninfected BMM (data not shown) supporting the
notion that Treg are killers of activated or pathogen-altered
BMM. Results were replicated in HIV-1ADA infected human
MDM cocultured with human Treg (Supplemental Figure 4A-C,
Supporting Information). In these assays human MDM were
shrunken and detached following Treg cocultivation (Supple-
mental Figure 4C, Supporting Information). Taken together, the
reductions seen in HIV-1p24 in macrophage culture superna-
tant ﬂuids by Treg likely reﬂect both antiviral innate immunity
and the killing of infected cells.
Treg Induces Infected BMM Apoptosis but not Pyrop-
tosis. Based on these observations of Treg-induced control of
viral infection, we next investigated molecular mechanisms
underlying the Treg induced cytotoxic responses. Immunoblots
for cleavage of procaspases-1 and 3 demonstrated that Treg
Figure 2. Treg Induces Virus-Infected BMM Death. (A) Treg induces HIV-1/VSV-infected BMM death shown by TUNEL assay plus confocal
immunoﬂuorescence microscopy and trypan blue staining plus light microscopy. For TUNEL assay, bright ﬁeld is shown in the top
panel and the corresponding ﬂuorescent ﬁeld is shown in the middle panel. Trypan blue staining is shown in the bottom panel (trypan
blue positive cells are indicated by yellow arrows). White scale bar represent 100 µm. (B) Graphs represent the mean percentage of
TUNEL positive BMM and trypan blue positive BMM counted and calculated from ﬁve different ﬁelds (data were pooled from three
independent experiments). Each bar represents a mean ( SD *p < 0.05, **p < 0.01, ***p < 0.001.
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speciﬁc. In contrast, Tcon induces infected BMM pyroptosis
through caspase-1 (Figure 3A, B). HIV-1/VSV infection itself
triggered caspase-1 activation in BMM and was enhanced by
Tcon but was reduced by Treg (Figure 3A). Densitometric
analysis of blots for caspase-1 subunits failed to reveal differ-
ences between caspase-1 p20 in HIV-1/VSV infected BMM
alone versus infected BMM cocultured with Tcon (16 to 18%
Figure 3. Treg and Tcon Induced Virus-Infected BMM Apoptosis and Pyroptosis. (A) Western blotting showed HIV-1/VSV infection
triggers caspase-1 activation in BMM, which was enhanced by Tcon coculture while attenuated by Treg coculture. Data shown are
representative of ﬁve independent experiments. (B) Western blotting showed Treg coculture activated caspase-3 pathway in HIV-1/
VSV infection BMM. Data shown are representative of ﬁve independent experiments. (C) Caspase-1 activation was measured by FLICA
assay plus immunoﬂuorescence microscopy. White scale bars represent 50 µm. Caspase-3 and 7 activation was measured by FLICA
assay plus immunoﬂuorescence microscopy. White scale bars represent 50 µm. (D) Proposed mechanisms Treg and Tcon use to
modulate HIV-1-infected macrophage functions. Upon infection, HIV-1 activates NF-κB and the inﬂammasome, which results in IL-1 
release. Tcon worsened this response by secretion of proinﬂammatory cytokines. In addition, those proinﬂammatory cytokines increase
mitochondrial activity, which could lead to energy exhaustion and pyroptosis. However, Treg use their anti-inﬂammatory cytokines to
extinguish the inﬂammation resulting from virus infection. Treg induce infected BMM apoptosis. Compared with apoptosis, pyroptosis
causes more ATP release. Excessive ATP is an important inﬂammatory molecule and could be hydrolyzed by ecto-nucleoside triphosphate
diphosphohydrolase CD39 and CD73 expressed on Treg. Moreover, Treg could transport cAMP to infected BMM and contribute to
inﬂammation resolution. The activation status of infected macrophage affects Th0 cell differentiation. For example, M1 induce Th1
and Th17, while M2 induce Th2 and iTreg. (E) Comparison of CD39 expression on Tcon and Treg was determined by ﬂow cytometric
analysis.
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caspase-1 p10 observed between HIV-1/VSV infected BMM
alone and HIV-1/VSV infected BMM cocultured with Tcon (11
to 17% when compared to actin). Futhermore, procaspase-1
was present in cell lysates from HIV-1/VSV infected BMM at
30% compared to actin, while 42% compared to actin from HIV-
1/VSV infected BMM cocultured with Tcon. (Figure 3A). In
addition, faint bands were observed in these blots for caspase-1
in the Treg treatment group and for caspase-3 in the Tcon
treatement group, suggesting much limited activation. Apop-
tosis induction by Treg and pyroptosis by Tcon was detected
independently using a Fluorochrome Inhibitor of Caspases
Assay (FLICA) utilizing binding of ﬂuorescent inhibitors to
speciﬁc active caspases (Figure 3C). Replicate observations were
also seen in human cells (Supplemental Figure 4A, Supporting
Information).
Comparisons between apoptosis and pyroptosis are il-
lustrated in Figure 3D. Brieﬂy, upon infection, HIV-1 activates
nuclear factor-kappa beta (NF-κB) and the inﬂammasome in
macrophages resulting in inﬂammatory cytokine release. Tcon
enhanced this response (Figure 3C). In addition, as demon-
strated, excessive activation commonly leads to energy exhaus-
tion and pyroptosis. When compared to apoptosis, pyroptosis
leads to increased adenosine triphosphate (ATP) release. Low
concentration of ATP is a critical apoptotic cell ﬁnd-me signal
for scavenger recruitment. On the contrary, excessive ATP
incites inﬂammation. Thus, enzymatic removal of excessive ATP
is one strategy to resolve such inﬂammation, which could be
achieved by Treg through its surface ectonucleoside triphos-
phate diphosphohydrolase, CD39 and CD73.
37 Indeed, Treg was
found to have signiﬁcantly greater CD39 expression than Tcon
(Figure 3E).
Treg Uses Granzymes and Perforin to Kill Infected
BMM. Previously, Grossman, et al. reported that activated
human naturally occurring Treg utilized the perforin-granzyme
A pathway to kill autologous target cells.
36 Meanwhile, they
demonstrated that activated mouse naturally occurring Treg
cells use perforin-granzyme B pathway to kill target cells. To
compare the expression proﬁle of granzymes in Tcon and Treg
before adding them to the infected BMM, we used confocal
microscopy and ﬂow cytometry to evaluate granzyme A and B
and perforin intensity. As shown in Supplemental Figure 5
(Supporting Information), both Tcon and Treg exhibited cy-
toplasmic granular staining of granzyme A, B and perforin. Treg
showed larger size and more abundant granules than Tcon
(Supplemental Figure 5A, Supporting Information). Flow cy-
tometry results conﬁrmed those observations (Supplemental
Figures 5B, C, Supporting Information).
To verify that Treg cells inserted perforin into the HIV-1-
infected cell membrane, an important step in transferring
granzymes to target cells, we used immunoblotting assays
to detect inserted perforin. A very clear band was observed
in Treg treated cell groups, while a diminished one was in
Tcon treated macrophages (Figure 4A). Next, we used
intracellular staining and confocal microscopy to visualize
granzymes and perforin in BMM. Both control and HIV-1/
VSV infected BMM showed no staining, indicating BMM do
not produce granzyme and perforin de novo. However,
cytoplasmic granular staining of granzymes and perforin
were seen in the Treg treated cells and less so in Tcon BMM
cocultivations (Figure 4B).
It is reported that granzyme A accesses the mitochondrial
matrix to cleave the novel identiﬁed substrate, NADH
dehydrogenase [ubiquinone] iron-sulfur protein 3 (NDUFS3),
throughperforintoinitiatecaspase-independentcelldeath.
38,39
Together with other subunits, NDUFS3 forms complex I of
the electron transport chain in mitochondria. Its cleavage
results in respiratory chain dysfunction and superoxide anion
generation. Using Western blotting, we found a cleaved
NDUFS3 band in HIV-1/VSV infected BMM cocultured with
Treg. In addition, faint bands were observed on immunoblots
of HIV-1/VSV infected BMM lysates with/out Tcon, indicat-
ing that NUDFS3 might be cleaved by other enzymes (Figure
4C). We also detected increased p38 phosphorylation in Treg
treated BMM (Figure 4A). Since altered NUDFS3 and phos-
phorylated p38 suggest that mitochondrial function was
affected, we used 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-
benzimidazolylcarbocyanine iodide (JC-1) staining and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay to evaluate its membrane potential and activity.
Fluorescence microscopy showed the loss of red JC-1 ag-
gregates ﬂuorescence and cytoplasmic diffusion of green
monomer ﬂuorescence in BMM following Treg coculture
(Figure 4D). Light microscopy showed reduced color intensi-
ties/cell and overall levels of MTT in Treg treated BMM. In
contrast, for infected BMM cocultured with Tcon, MTT
staining intensities were increased in infected cells (Supple-
mental Figure 6A, Supporting Information). Such Treg
induced cytotoxicity on infected BMM was cell-cell contact
dependent as demonstrated by transwell cocultures (Supple-
mental Figure 6B, Supporting Information).
Treg Induces Virus Infected BMM Phenotypic Switches
by Intercellular Transportation of cAMP. We noted that
among all cell death assays we used in this study, only
around 50% of cells are killed by Treg. In addition, greater
than 98% of BMM were infected as determined by p24
immunoﬂurescence staining (Supplemental Figure 1B, Sup-
porting Information). So why did Treg only kill 50% of the
cells? We observed that the privileged BMM underwent
remarkable cytoskeletal rearrangement (Figure 5A), which
may indicate its polarization switching.
40 As shown in Figure
5A, Treg induced changes in infected BMM morphology from
a polarized to a rounded appearance with contracted
processes showing redistribution of actin from focal adhe-
sions to a cortical distribution. Such alterations paralleled
functional outcomes in the BMM proteome (Table 1 and data
not shown). We hypothesized that a polarization switch in
this model could be due to either direct effects of Treg or in
response to cytotoxicity induced by Treg. To test this, we
used Western blotting to detect expression of inducible nitric
oxide synthase (iNOS) and arginase-1 (Arg-1), which are
putative markers for classical activation macrophage (M1)
and alternative activation macrophage (M2), respectively. We
found that Treg downregulated iNOS 35-fold, with a con-
comitant 18-fold upregulation of Arg-1 (Figure 5B). The
decreased NO production by HIV-1/VSV-infected BMM
cocultured with Treg supports this transformation. This is
in stark contrast to the signiﬁcantly increased NO production
by infected BMM in the presence of Tcon (Figure 5C).
To decipher the mechanisms underlying this phenotypic
switch in a strictly cell contact-dependent manner, we
measured the levels of cyclic adenosine monophosphate
(cAMP) in the culture supernatants and cell lysates, based
on two important ﬁndings: cAMP is reported to modulate
iNOS and Arg-1 expression in macrophages;
41 and Treg is
reported to transport cAMP to target cells via gap junctions.
42
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culture supernatants (Figure 5D, E). However, compared with
Tcon, Treg harbors higher levels of cAMP. And most impor-
tantly, coculture of infected BMM with Treg resulted in
Figure 4. Treg Uses Granzyme A, B and Perforin to Kill Virus-Infected BMM. (A) Western blotting demonstrating increased p38
phosphorylation (upper panel) and perforin insertion (middle panel), which were normalized to  -actin (bottom panel) in HIV-1/VSV
infected BMM cocultured with Treg compared with HIV-1/VSV infected BMM cocultured with Tcon groups. Data shown are representative
of three independent experiments. (B) Confocal immunoﬂuorescences of BMM with speciﬁc monoclonal antibodies against granzyme
A (upper panel), granzyme B (middle panel) and perforin (bottom panel) show cytoplasmic granular staining of granzyme A (red),
granzyme B (red) and perforin (red) in Tcon and Treg treated groups. Both control and HIV-1/VSV infected groups showed no staining
of those antibodies, which means BMM did not produce granzyme and perforin. Higher intensity of granzyme and perforin were seen
in the Treg treated group compared with the Tcon treated group. Data shown are representative of three independent experiments.
White scale bars represent 5 µm. (C) Cleaved NDUFS3, the 30 kDa subunit of mitochondrial complex I and the important substrate of
granzyme A, was shown in HIV-1/VSV infected BMM cocultured with Treg group by Western blotting. Data shown are representative
of three independent experiments. (D) Membrane potential-dependent staining of mitochondria in HIV-1/VSV infected BMM by JC-1
visualized by ﬂuorescence microscopy showed the loss of red JC-1 aggregates ﬂuorescence and cytoplasmic diffusion of green monomer
ﬂuorescence following coculture with Treg.
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(Figure 5E). Since cAMP in supernatants is undetectable, we
believe it may have traversed membranes via gap junctions.
An alternative hypothesis is that production of adenosine
as a result of coculture of Treg expressing CD39 likely contrib-
uted to the increased intracellular cAMP production through
adenosine receptor signaling. Both mechanisms could be
involved and would be up to future studies to determine.
Treg Elicits Infected BMM-Mediated Neuroprotective
Responses. Given the multiple mechanisms of Treg presented
herein used to modulate HIV-1/VSV infected macrophages
(Supplemental Figure 7, Supporting Information), we expected
that Treg must have neuroprotective roles due to their abilities
to inhibit viremia and resolve inﬂammation. Indeed, our lab
recently showed the neuroprotective properties of Treg in an
HIVE model.
9 To conﬁrm this anticipation, we used condi-
tioned medium to treat primary neurons in vitro. Neuropro-
tection is readily observed in Treg-treated BMM groups (Figure
6). Comparisons between neurons treated with conditioned
media from HIV-1/VSV infected BMM in the absence or
presence of Treg and Tcon are shown (Figure 6 and Supple-
mental Table 1, Supporting Information). Furthermore, addi-
tion of media from uninfected macrophages was not observed
to result in any neurotoxicity (Figure 6 and data not shown).
Figure 5. Treg Transforms the Infected BMM. (A) Treg induces HIV-1/VSV infected BMM morphology change from elongation to
roundness shown by confocal immunoﬂuorescence microscopy (zoomed part is shown at the bottom panel). White scale bars represent
20 µm. (B) Western blotting showed Treg downregulated iNOS, while upregulated arginase-1. (C) The concentration of NO in supernatant
was measured with Griess test. Treg inhibited NO production from HIV-1/VSV infected BMM, ***p < 0.001. (D) Concentrations of
cAMP in the lysate (L) and supernatant (S) of Tcon or Treg were detected by ELISA, *p < 0.05 (E) Concentrations of cAMP in the lysate
and supernatant of BMM with different treatments. The cAMP in the supernatant was undetectable, while its concentration in lysate
increased in Treg treated group. ***p < 0.001.
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Broad functions of Treg were identiﬁed in the current report
and beyond what is known for immune suppression. For the
HIV-1-infected macrophage this includes enhancement of
innate antiviral immunity, polarization in control of inﬂam-
matory activities and toxic secretory responses, and immuno-
surveillance in the killing of virus-infected macrophages. For
the latter Treg utilize several mechanisms including granzyme
A, B and perforin. In addition, Treg also altered redox biology
to lower levels of oxidative stress.
9 These results, taken together,
demonstrate a much broader range of functions of these
regulatory cells than previously appreciated and help explain
their control of disease. This of course includes HAND which
is rarely seen during subclinical disease and immunocompe-
tence.
43
The abilities of ART in lowering HAND severity have long
been appreciated.
44 The mechanisms described revolve around
the number and function of CD8+ CTLs resulting in the
elimination of infected cells. However, ART also preserves
CD4+ T cell populations. CD4+ T cells orchestrate innate and
adaptive immune responses to HIV. Importantly, Th1, Th2,
Th17 and Treg are heterogeneous in function based, in large
measure, on their cytokine secretion and speciﬁc transcription
factor expression. Indeed, cytokine proﬁles, tissue environment,
microbial infection or injuries affect the cells differential fates.
35
It has long been appreciated that Treg control immune
responses to infections, but whether the ultimate outcome from
Treg actions in disease is protective or destructive remains
unresolved.
14,45,46 For the better part of its existence Treg serve
to limit damage caused by excessive virus-induced inﬂamma-
tory responses.
47 However, for HIV-1 infection, its role can be
seen as a double-edged sword. Treg-mediated suppression can
lead to cessation of antiretroviral immune responses and in
so doing allow productive viral replication.
15,20,48 It is possible
that effector T cell responses could prevent Treg-mediated
suppression of antiviral responses; especially those mediated
through soluble factors, but could still allow Treg killing of
infected macrophages. Moreover, excessive immune activation
can incite secondary disease manifestations.
49,50 On the other
hand, secondary end organ effects of virus that include kidney,
liver, lung, and brain pathologies could be attenuated by Treg
through control of inﬂammatory responses. It is of interest to
note that changes in numbers and function of Treg in lymphoid
tissues and blood during HIV-1 infection are evolutionary.
26,51
Commonly, an increased frequency of Treg is observed in HIV-
1-infected individuals and notably in those with readily detect-
able plasma viremia.
52 Thus, whether Treg are ultimately
beneﬁcial for HIV disease still remains an active source of
discussion and debate.
9,52-54
For HAND, the roles of Treg are likely better deﬁned.
9
Indeed, our previous works in murine models of HIVE using
infected bone marrow-derived macrophages showed that fol-
lowing adoptive transfer of Treg astrogliosis and microgliosis
were attenuated with substantive neuroprotection.
9 Such ob-
servations parallel our laboratory’s results in an experimental
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of PD.
7,28
The current study clearly illustrates control of inﬂammatory
effector functions by CD4+CD25+ Treg for HIV-infected mac-
rophages. Furthermore, Treg are effective in inhibiting HIV-1
replication and release.
9 Indeed, we recently demonstrated Treg
abiltity to migrate to sites of inﬂammation in the brains of HIVE
mice resulting in decreased HIV-1p24 and gliosis, with a
concomitant increase in neurotrophins.
55 These functions
support a multifaceted and beneﬁcial role of Treg in HIV
infection and help further explain the neuroprotection pro-
vided, notably during ART where adaptive immunity is largely
preserved.
56
The observations that Treg induce interferon-mediated
antiviral immunity and kill HIV-1-infected MPs by caspase-3
and granzyme/perforin pathways, depleting cellular sources of
neurotoxic factors is of importance. Indeed, Treg are capable
of killing a variety of autologous target effector cells, including
CD4+ and CD8+ T cells, CD14+ monocytes, and dendritic
cells.
36 Furthermore, Treg preferentially kill activated T cells.
36
Our results demonstrate that HIV-activated M1 macrophages
are also killed more so than uninfected cells. The phenotypic
switch from M1 to M2 for the macrophages is attributed to
Treg in the setting of HIV infection but the mechanism by
which this occurs is yet to be determined, but may involve both
cytokine dependent and independent pathways.
57 Indeed, our
work suggests that direct cAMP transfer to infected cells and/
or adenosine signaling are responsible, in part, for the pheno-
typic switch.
42,58,59 Adenosine signaling has been shown in
macrophages to reduce the production of pro-inﬂammatory
cytokines including TNF-R, IL-12, MIP-1, and NO, as well as
increase production of IL-10.
60,61 Furthermore, adenosine
Figure 6. Treg-induced infected BMM elicits neuroprotection. Tubulin staining shows persevered neuronal dendrites in groups cultured
with both CM1 (upper panel) and CM2 (bottom panel) from Treg treated HIV-1/VSV-infected BMM, which was not seen in Tcon derived
CM. Moreover, CM2 from the Tcon treated group exhibits more toxicity than the infected group, which suggests that the proinﬂammatory
cytokines are more destructive than viral proteins. White scale bar represents 50 µm.
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pathways, consistent with our ﬁndings.
62 Thus, killing of HIV-
1-infected BMM by Treg may be a result of both the antiviral
response itself and the BMM activation state.
Regardless of the mechanism, a Treg directed phenotypic
switch from M1 to M2 phenotype is advantageous for neuronal
survival. The M1 phenotype is pro-inﬂammatory and is associ-
ated with neurodegeneration and increased viremia.
63,64 An M2
phenotype however, is associated with tissue repair, anti-
inﬂammatory cytokine production, and decreased ROS pro-
duction.
9,65,10 Thus an M2 phenotypic transformation in the
setting of an inﬂammatory environment such as in HAND can
contribute to resolution of inﬂammation and neuroprotection
observed with Treg treatment.
9 Furthermore, some evidence
suggests that M2 macrophages retain their phagocytic activity
and have enhanced intracellular killing capability.
66
As major CNS APCs and a source of cytokines and chemok-
ines, perivascular macrophages and microglia strongly inﬂu-
ence the activation state of astrocytes, and inﬂuence the
trafﬁcking of adaptive immune cells into the brain.
67 Astrocytes
also can contribute to HIV-1 induced CNS damage as a potent
source of CXCL10 production in HIV-1-infected individuals,
especially with TNF-R and IFN-γ production by MPs. Impor-
tantly, Treg are able to decrease the production of these
cytokines that could ultimately diminish astrocyte CXCL10
production.
9 Furthermore, HIV-1-infected macrophages induce
astrocyte CXCL8 secretion, a chemokine that enhances chemo-
taxis of neutrophils and monocytes in HAD.
68 These ﬁndings
illustrate the interaction between glia and immune cells that
can contribute to neuroinﬂammation or, when inﬂuenced by
Treg, resolution of inﬂammation. Recognition of the multifac-
eted functions of Treg is an important ﬁrst step toward a
complete understanding of the broad roles of adaptive im-
munity in the setting of HIV infection and particularly that of
the CNS. This is certainly a vital part of the complex cellular
and viral interplay present during HAND. Indeed, Treg also
have the capacity to attenuate inﬂammation in a range of
neurodegenerative diseases and may be harnessed for thera-
peuptic gain.
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